Cover Image
市場調查報告書

非小細胞肺癌:KOL的考察

Non-Small Cell Lung Cancer: KOL Insight

出版商 FirstWord 商品編碼 336411
出版日期 內容資訊 英文 209 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
非小細胞肺癌:KOL的考察 Non-Small Cell Lung Cancer: KOL Insight
出版日期: 2015年07月01日 內容資訊: 英文 209 Pages
簡介

非小細胞肺癌 (NSCLC) 的治療流程急速發展,日益複雜化、細分化。

關於本報告提供非小細胞肺癌 (NSCLC) 的市場及開發平台相關確立的治療方法、新的治療方法重點調查,主要12名KOL的採訪,為您概述為以下內容。

主要的調查內容

  • 可能破壞、再形成NSCLC治療流程的新藥為何?
  • 可能大幅影響未來的NSCLC治療的臨床試驗為何?
  • 目前標靶治療、免疫療法的利用如何發展,以及發展的可能性?
  • 新治療藥、未來的治療藥相關專家非常關心的事為何?
  • 生物標記、患者區分帶給未來的NSCLC治療怎樣的影響?

調查對象的目前治療藥

  • 免疫療法
    • Opdivo (nivolumab; Bristol-Myers Squibb)
  • EGFR變異陽性NSCLC
    • Tarceva (erlotinib; Astellas/Roche)
    • Iressa (gefitinib; AstraZeneca)
    • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)
  • ALK陽性NSCLC
    • Zykadia (ceritinib; Novartis)
  • ALK、EGFR變異陰性NSCLC
    • Avastin (bevacizumab; Roche)
    • Vargatef (nintedanib; Boehringer Ingelheim)
    • Cyramza (ramucirumab; Eli Lilly)

調查對象的未來治療藥

  • 免疫療法
    • Keytruda (pembrolizumab; Merck & Co.)
    • Atezolizumab (MPDL3280A; Roche)
    • Durvalumab (MEDI4736; AstraZeneca)
    • Yervoy (ipilimumab; BMS)
  • EGFR變異陽性NSCLC
    • Mereletinib (AZD9291; AstraZeneca)
    • Rociletinib (CO-1686; Celgene/Clovis Oncology)
    • Dacomitinib (PF-00299804; Pfizer/SFJ Pharmaceuticals)
    • Patritumab (AMG 888; Amgen/第一三共)
  • ALK陽性NSCLC
    • Alectinib (RO5424802/CH5424802; Roche)
  • ALK、EGFR變異陰性NSCLC
    • Selumetinib (AZD6244; Array/AstraZeneca)
    • Veliparib (ABT-888; AbbVie)
    • Gemzar (necitumumab; Eli Lilly)
    • Bavituximab (Peregrine)
    • Abemaciclib (LY2835219; Eli Lilly)
    • Ganetespib (STA-9090; Synta)

KOL

  • 北美的KOL
  • 歐洲的KOL
目錄
Product Code: 596200416

The rapidly evolving non-small cell lung cancer (NSCLC) treatment algorithm is becoming increasingly complex and fragmented. Every advancement brings a new set of questions and concerns. This comprehensive report presents all the facts as they stand today, plus expert insights on the likely state of affairs tomorrow.

Which therapies are most likely to make a significant difference in the NSCLC field? Will we learn to use them to their fullest potential and in the optimal sequence? Can we afford them?

Non-Small Cell Lung Cancer: KOL Insight provides a review of the marketplace and the pipeline with an emphasis on established and emerging treatment pathways. Interviews with 12 KOLs add future-facing perspective to the data. The result is an insider's guide to the intricacies of a critical and complex market.

Top Benefits

  • Understand how your product is perceived, or is likely to be perceived, by the marketplace
  • Learn about the strengths and weaknesses of your competitors
  • Consider new positioning approaches that will put your product in the most favorable light possible
  • Understand opportunities and threats in the marketplace
  • UGain the insights required to better direct your sales and/or marketing teams toward success

Critical Questions Answered

  • Which new drugs are likely to disrupt or reshape the treatment algorithm for NSCLC?
  • Which clinical trials have the greatest potential to impact the future treatment of NSCLC?
  • How is the use of current targeted and immune therapies evolving, or likely to evolve?
  • What are the experts' greatest concerns about new and future therapies?
  • How will biomarkers and patient segmentation affect the future of treatment of NSCLC?

Key Areas Covered

  • Currently used, and late-stage pipeline, targeted and immune therapies for NSCLC
  • Summaries and analyses of the most significant, ongoing late-stage clinical trials
  • Overviews of current treatment algorithms based on patient segment, line of therapy, and patient characteristics
  • Considerations of treatment cost versus efficacy

Current Treatments Covered

Immunotherapy

  • Opdivo (nivolumab; Bristol-Myers Squibb)

EGFR mutation-positive NSCLC

  • Tarceva (erlotinib; Astellas/Roche)
  • Iressa (gefitinib; AstraZeneca)
  • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)

ALK-positive NSCLC

  • Zykadia (ceritinib; Novartis)

ALK and EGFR mutation-negative NSCLC

  • Avastin (bevacizumab; Roche)
  • Vargatef (nintedanib; Boehringer Ingelheim)
  • Cyramza (ramucirumab; Eli Lilly)

Pipeline Therapies Covered

Immunotherapy

  • Keytruda (pembrolizumab; Merck & Co.)
  • Atezolizumab (MPDL3280A; Roche)
  • Durvalumab (MEDI4736; AstraZeneca)
  • Yervoy (ipilimumab; BMS)

EGFR mutation-positive NSCLC

  • Mereletinib (AZD9291; AstraZeneca)
  • Rociletinib (CO-1686; Celgene/Clovis Oncology)
  • Dacomitinib (PF-00299804; Pfizer/SFJ Pharmaceuticals)
  • Patritumab (AMG 888; Amgen/Daiichi Sankyo)

ALK-positive NSCLC

  • Alectinib (RO5424802/CH5424802; Roche)

ALK and EGFR mutation-negative NSCLC

  • Selumetinib (AZD6244; Array/AstraZeneca)
  • Veliparib (ABT-888; AbbVie)
  • Gemzar (necitumumab; Eli Lilly)
  • Bavituximab (Peregrine)
  • Abemaciclib (LY2835219; Eli Lilly)
  • Ganetespib (STA-9090; Synta)

Key Opinion Leaders

KOLs from North America:

  • Paul Bunn, Distinguished Professor, Division of Medical Oncology, University of Colorado Edward Garon, Associate Professor, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
  • Giuseppe Giaccone, Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University, Washington, DC
  • Leora Horn, Assistant Professor of Medicine (Haematology/Oncology) and Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Tennessee
  • Joan Shiller, Deputy Director of the Simmons Comprehensive Cancer Center and Division Director of Hematology/Oncology, University of Texas-Southwestern Medical Center, Texas
  • Mark Socinski, Professor of Medicine and Thoracic Surgery, University of Pittsburgh School of Medicine, Pennsylvania

KOLs from Europe:

  • Ahmed Awada, Professor and Head of the Medical Oncology Clinic, Jules Bordet Institute, Brussels & Free Universities, Brussels, Belgium
  • Federico Cappuzzo, Professor and Director of Medical Oncology, Ospedale Civile di Livorno, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy
  • Solange Peters, Head of Thoracic Malignancies Program, Department of Oncology, University of Lausanne, Switzerland
  • David Planchard, Associate Professor, Department of Medical Oncology (Thoracic Oncology Group), Gustave-Roussy, France
  • Nick Thatcher, previously held the post of Professor of Medical Oncology at the Christie Hospital NHS Trust in Manchester, England
  • Anonymous KOL, Germany
Back to Top